A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single (Part 1) and Multiple (Part 2) Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of M281 Administered to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2017
At a glance
- Drugs M 281 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Momenta Pharmaceuticals
- 14 Nov 2017 Status changed from recruiting to completed.
- 02 Aug 2017 According to a Momenta Pharmaceuticals media release, the company expects to complete the multiple ascending dose portion of the study in August 2017.
- 21 Feb 2017 According to a Momenta Pharmaceuticals media release, the company plans to report the full data from the single and multiple ascending dose portions of the study in the second half of 2017.